Revolution Medicines (RVMD) Research & Development (2019 - 2026)

Revolution Medicines has reported Research & Development for 8 years, with the latest figure at $344.0 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 67.18% year-over-year to $344.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 65.39% YoY), and the FY2025 full-year result was $987.3 million, up 66.72% from the prior year.
• Research & Development for Q1 2026 stood at $344.0 million, up from $294.9 million in the prior quarter.
• The five-year high for Research & Development was $344.0 million in Q1 2026, with the low at $56.5 million in Q1 2022.
• Average Research & Development over 5 years is $153.0 million, with a median of $134.9 million recorded in 2024.
• Peak annual rise in Research & Development reached 124.54% in 2023, while the deepest fall reached 22.05% in 2023.
• Tracing RVMD's Research & Development over 5 years: stood at $66.1 million in 2022, then surged by 124.54% to $148.5 million in 2023, then climbed by 26.68% to $188.1 million in 2024, then jumped by 56.8% to $294.9 million in 2025, then increased by 16.62% to $344.0 million in 2026.
• The last three Research & Development figures came in at $344.0 million (Q1 2026), $294.9 million (Q4 2025), and $262.5 million (Q3 2025), per Business Quant data.

Peer Comparison